Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Capacity Expansions, New Technologies, and Quarterly Results - Research Report on Thermo Fisher, Life Technologies, Agilent,



Capacity Expansions, New Technologies, and Quarterly Results - Research Report
    on Thermo Fisher, Life Technologies, Agilent, PAREXEL, and PerkinElmer

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, August 12, 2013

NEW YORK, August 12, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Thermo
Fisher Scientific, Inc. (NYSE: TMO), Life Technologies Corporation (NASDAQ:
LIFE), Agilent Technologies Inc. (NYSE: A), PAREXEL International Corporation
(NASDAQ: PRXL), and PerkinElmer Inc. (NYSE: PKI). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Thermo Fisher Scientific, Inc. Research Report

On August 1, 2013, Thermo Fisher Scientific Inc. (Thermo Fisher) announced the
expansion of its global cell culture and bioprocessing capabilities through a
new manufacturing plant in Tuas, Singapore. According to the Company, the
facility will be the first-ever cell culture dry powder media (DPM) production
site in Singapore, which is designed to address the increased global
requirements from biopharmaceutical companies to mitigate critical raw
material supply risks. "Asia continues to be our fastest-growing market and a
central contributor to our growth," said Greg Herrema, President of
Biosciences at Thermo Fisher Scientific. "Our new Singapore facility further
strengthens our global presence, expands our manufacturing infrastructure and
establishes local production capabilities to meet increased demand for
biologic drug discovery and development in Asia." The Full Research Report on
Thermo Fisher Scientific, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/45ed_TMO]

--

Life Technologies Corporation Research Report

On August 1, 2013, Life Technologies Corp. (Life Technologies) launched its
first state-of-the-art forensics laboratory in Gurgaon, India. As per the
Company, this new laboratory will provide DNA profiling services to help
accelerate the sampling process, while reducing costs and saving time. "Life
Technologies DNA Forensics Laboratory will reduce the burden on existing
Forensic System and address the requirements of DNA database generation for
un-identified dead bodies or other crime investigations," said Devashish Ohri,
Managing Director of Life Technologies South Asia. "We are looking forward to
partnering with the State and Central Government laboratories to assist in the
establishment of a DNA database project." The Full Research Report on Life
Technologies Corporation - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/d5de_LIFE]

--

Agilent Technologies Inc. Research Report

On August 1, 2013, Agilent Technologies Inc. (Agilent) announced a recent
development of its Dissolution Workstation Software. According to Agilent, its
new software supports laboratory capabilities to build, edit, search,
retrieve, execute and archive all dissolution methods and test reports from a
single interface. "One of the greatest enhancements is the addition of
vibration monitoring to the Dissolution Workstation Software," said Allan
Little, Marketing Director for Agilent's Dissolution Systems business. "This
added benefit may be used during early research to develop internal tolerances
for specific methods, or as part of a quality-control initiative for
well-established methods." Agilent explained that dissolution is a technique
used in the pharmaceutical industry to determine the rate at which pure active
pharmaceutical ingredients dissolve. The Full Research Report on Agilent
Technologies Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/075e_A]

--

PAREXEL International Corporation Research Report

On August 7, 2013, Parexel International Corp. (Parexel) reported its Q4 FY
2013 financial results (period ended June 30, 2013), posting service revenue
total of $463.1 million, up 18% YoY. GAAP operating margin in Q4 FY 2013 was
8.3%, up 180 basis points compared to Q4 FY 2012. GAAP diluted EPS increased
79.3% YoY to $0.52. Commenting on the future outlook of the Company, Mr. Josef
H. von Rickenbach, PAREXEL's Chairman and Chief Executive Officer, stated, "We
believe that the market for our products and services remains solid, and that
PAREXEL's competitive position is favorable.  I'm excited about Fiscal Year
2014, and remain confident in our ability to generate further benefits for our
shareholders." The Company anticipates its Q1 FY 2014 revenues to be in the
range of $455 million to $460 million, and GAAP EPS in the range of $0.42 to
$0.46. The Full Research Report on PAREXEL International Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/067b_PRXL]

--

PerkinElmer Inc. Research Report

On August 1, 2013, PerkinElmer Inc. (PerkinElmer) reported its Q2 2013
financial results with reported revenues of $543.3 million, compared to $521.8
million in Q2 2012. GAAP diluted EPS from continuing operations was $0.24
compared to $0.29 in Q2 2012. Adjusted EPS was $0.51 compared to $0.53 in Q2
2012. GAAP operating income totaled $39.7 million compared to $49.8 million in
Q2 2012. "We were able to deliver sequential revenue improvements in the areas
that were under pressure in the first quarter while the remaining portfolio
continued to perform well," said Robert Friel, Chairman and Chief Executive
Officer of PerkinElmer. "Our second quarter performance gives us confidence in
our ability to deliver organic growth and improved profitability in the back
half of the year." The Company anticipates full year 2013 GAAP EPS in the
range of $1.40 to $1.47. The Full Research Report on PerkinElmer Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/2016_PKI]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement